Nemes Rush Group
NVO icon

Nemes Rush Group’s Novo Nordisk NVO Stock Holding History

Nemes Rush Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.04K Buy
107
+1
+0.9% +$46 ﹤0.01% 685
2026
Q2 		$5.1K Hold
106
– – ﹤0.01% 662
2026
Q1 		$3.88K Sell
106
-112
-51% -$5.31K ﹤0.01% 665
2025
Q4 		$11.1K Buy
218
+55
+34% +$2.81K ﹤0.01% 536
2025
Q3 		$9.02K Sell
163
-17,961
-99% -$1.05M ﹤0.01% 500
2025
Q2 		$1.25M Sell
18,124
-78,992
-81% -$5.37M 0.14% 90
2025
Q1 		$6.74M Buy
97,116
+13,951
+17% +$1.15M 0.85% 39
2024
Q4 		$7.15M Sell
83,165
-10,198
-11% -$1.1M 0.88% 37
2024
Q3 		$12M Sell
93,363
-6,915
-7% -$922K 1.74% 19
2024
Q2 		$14.3M Buy
100,278
+6,114
+6% +$810K 1.97% 15
2024
Q1 		$12.1M Buy
94,164
+93,708
+20,550% +$11.2M 1.73% 19
2023
Q4 		$47.2K Buy
456
+27
+6% +$2.67K 0.01% 260
2023
Q3 		$39K Sell
429
-93
-18% -$8.19K 0.01% 279
2023
Q2 		$42.2K Buy
+522
New +$42.6K 0.01% 286

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Everett Harris & Co
Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Saratoga Research & Investment Management
Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return
Markel Group
Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Oppenheimer Asset Management
Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Nemes Rush Group's NVO Position: Q3 2026 in Review

Nemes Rush Group increased its Novo Nordisk (NVO) stake by 0.94% in Q3 2026, buying an estimated $46 and bringing the position to 107 shares worth $4.04K. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Nemes Rush Group first reported a position in NVO in Q2 2023 and has held it in 14 quarters since. The position peaked at $14.3M in Q2 2024. 696 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Nemes Rush Group held 107 shares of Novo Nordisk worth $4.04K as of Q3 2026.
  • Nemes Rush Group bought 1 Novo Nordisk share in Q3 2026, an estimated $46.
  • Novo Nordisk made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #685 holding.
  • Nemes Rush Group first reported a position in Novo Nordisk in Q2 2023 and has held it in 14 quarters since.
  • Nemes Rush Group's Novo Nordisk position peaked at $14.3M in Q2 2024.
  • 696 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.